News Patients denied thyroid cancer drug in England Eisai considers legal action over funding "black hole".
News Gilead cancer drug can stay on EU market Safety experts recommend antibiotics after Zydelig treatment.
News AZ pays Heptares $10m as cancer trial begins Phase 1 study of immuno-oncology drug candidate begins.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
